Literature DB >> 9228052

The organization, promoter analysis, and expression of the human PPARgamma gene.

L Fajas1, D Auboeuf, E Raspé, K Schoonjans, A M Lefebvre, R Saladin, J Najib, M Laville, J C Fruchart, S Deeb, A Vidal-Puig, J Flier, M R Briggs, B Staels, H Vidal, J Auwerx.   

Abstract

PPARgamma is a member of the PPAR subfamily of nuclear receptors. In this work, the structure of the human PPARgamma cDNA and gene was determined, and its promoters and tissue-specific expression were functionally characterized. Similar to the mouse, two PPAR isoforms, PPARgamma1 and PPARgamma2, were detected in man. The relative expression of human PPARgamma was studied by a newly developed and sensitive reverse transcriptase-competitive polymerase chain reaction method, which allowed us to distinguish between PPARgamma1 and gamma2 mRNA. In all tissues analyzed, PPARgamma2 was much less abundant than PPARgamma1. Adipose tissue and large intestine have the highest levels of PPARgamma mRNA; kidney, liver, and small intestine have intermediate levels; whereas PPARgamma is barely detectable in muscle. This high level expression of PPARgamma in colon warrants further study in view of the well established role of fatty acid and arachidonic acid derivatives in colonic disease. Similarly as mouse PPARgammas, the human PPARgammas are activated by thiazolidinediones and prostaglandin J and bind with high affinity to a PPRE. The human PPARgamma gene has nine exons and extends over more than 100 kilobases of genomic DNA. Alternate transcription start sites and alternate splicing generate the PPARgamma1 and PPARgamma2 mRNAs, which differ at their 5'-ends. PPARgamma1 is encoded by eight exons, and PPARgamma2 is encoded by seven exons. The 5'-untranslated sequence of PPARgamma1 is comprised of exons A1 and A2, whereas that of PPARgamma2 plus the additional PPARgamma2-specific N-terminal amino acids are encoded by exon B, located between exons A2 and A1. The remaining six exons, termed 1 to 6, are common to the PPARgamma1 and gamma2. Knowledge of the gene structure will allow screening for PPARgamma mutations in humans with metabolic disorders, whereas knowledge of its expression pattern and factors regulating its expression could be of major importance in understanding its biology.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9228052     DOI: 10.1074/jbc.272.30.18779

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  346 in total

Review 1.  Peroxisome proliferator-activated receptors: lipid binding proteins controling gene expression.

Authors:  Marc van Bilsen; Ger J van der Vusse; Andries J Gilde; Martijn Lindhout; Karin A J M van der Lee
Journal:  Mol Cell Biochem       Date:  2002-10       Impact factor: 3.396

2.  What is a functional locus? Understanding the genetic basis of complex phenotypic traits.

Authors:  Edward A Ruiz-Narváez
Journal:  Med Hypotheses       Date:  2011-02-01       Impact factor: 1.538

3.  Thiazolidinedione use and ulcerative colitis-related flares: an exploratory analysis of administrative data.

Authors:  Jennifer L Lund; Til Stürmer; Carol Q Porter; Robert S Sandler; Michael D Kappelman
Journal:  Inflamm Bowel Dis       Date:  2011-03       Impact factor: 5.325

4.  Peroxisome proliferator activated receptor-γ and traumatic brain injury.

Authors:  Lei Qi; Asha Jacob; Ping Wang; Rongqian Wu
Journal:  Int J Clin Exp Med       Date:  2010-09-23

5.  Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemia.

Authors:  Twee Tsao; Steven Kornblau; Stephen Safe; Julie C Watt; Vivian Ruvolo; Wenjing Chen; Yihua Qiu; Kevin R Coombes; Zhenlin Ju; Maen Abdelrahim; Wendy Schober; Xiaoyang Ling; Dimitris Kardassis; Colin Meyer; Aaron Schimmer; Hagop Kantarjian; Michael Andreeff; Marina Konopleva
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

6.  New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.

Authors:  Angelika Lüdtke; Janine Buettner; Hartmut H-J Schmidt; Howard J Worman
Journal:  J Med Genet       Date:  2007-09       Impact factor: 6.318

7.  Thiazolidinediones as anti-cancer agents.

Authors:  Carmelo Blanquicett; Jesse Roman; C Michael Hart
Journal:  Cancer Ther       Date:  2008

8.  Role of the ACE ID and PPARG P12A Polymorphisms in Genetic Susceptibility of Diabetic Nephropathy in a South Indian Population.

Authors:  Lakkakula Vks Bhaskar; Sultana Mahin; Raju Thankabai Ginila; Periyasamy Soundararajan
Journal:  Nephrourol Mon       Date:  2013-05-26

9.  Genetic variation in the inflammation and innate immunity pathways and colorectal cancer risk.

Authors:  Hansong Wang; Darin Taverna; Daniel O Stram; Barbara K Fortini; Iona Cheng; Lynne R Wilkens; Terrilea Burnett; Karen W Makar; Noralane M Lindor; John L Hopper; Steve Gallinger; John A Baron; Robert Haile; Laurence N Kolonel; Brian E Henderson; Polly A Newcomb; Graham Casey; David Duggan; Cornelia M Ulrich; Loïc Le Marchand
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-09-17       Impact factor: 4.254

Review 10.  PPARgamma in human and mouse physiology.

Authors:  Sami Heikkinen; Johan Auwerx; Carmen A Argmann
Journal:  Biochim Biophys Acta       Date:  2007-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.